Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268413 | 0.83 | GRK6 (0.40) | GRK6OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL8278554 | 0.77 | ALDH1A1 (0.41) | TARBP2ALDH1A1CYP1A2MAPK1KMT2A | |
| SCHEMBL8048488 | 0.77 | OGFRL1 (0.47) | GRK6OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL5038584 | 0.75 | GRK6 (0.44) | GRK6OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL16268945 | 0.74 | CYP2C19 (0.39) | GRK6TARBP2CYP1A2KMT2AKDM4E | |
| SCHEMBL15145571 | 0.73 | TARBP2 (0.40) | GRK6OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL30668018 | 0.72 | GRK6 (0.43) | GRK6OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3198143 | 0.70 | KDM4E (0.36) | TARBP2ALDH1A1CYP1A2MAPK1KMT2A | |
| SCHEMBL16268118 | 0.70 | ALDH1A1 (0.42) | ALDH1A1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL2681871 | 0.70 | CNR2 (0.50) | GRK6OGFRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004109-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | GRK6 2597/4885OGFRL1 3679/4885OPRM1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.